Cocrystal Pharma, Inc. — Income Charts
8 years of history · ending 2020-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$2M
Cost of Revenue
—
Gross Profit
—
R&D↓-94.1% -$96M
$6M
D&A↓-21.9% -$44K
$157K
Operating Income↑+90.9% +$96M
$-10M
EBITDA↑+91.1% +$96M
$-9M
Interest Expense
$8K
Interest Income↓-450.0% -$9K
$-7K
Other Income/Expense↓-103.8% -$1M
$-54K
Pretax Income↑+90.7% +$95M
$-10M
Tax Provision↓-26019.2% -$14M
$-14M
Net Income↑+87.1% +$65M
$-10M
Gross Margin
—
Operating Margin
-476.0%
Net Margin
-479.0%
Effective Tax Rate↓-12.8pts
21.7%
Deferred Tax Assets↑+492.6% +$17M
$20M
Deferred Tax Liabilities↑+100.1% +$20M
$20K
DTA Valuation Allowance↓-14.5% -$3M
$20M
Tax Credit Carryforwards↓-99.9% -$258M
$203K
NOL Carryforwards↓-16.4% -$3M
$17M
ETR (Continuing Operations)
0.0%
ETR Federal Statutory↓-13.0pts
21.0%
ETR State + Local (pp)↑+0.1pts
0.5%
ETR Foreign Differential (pp)
—
Operating Lease Cost↓-48.1% -$166K
$179K
Revenue YoY Variation
-69.3%
Income YoY Variation↑+176.3pts
80.2%